Sei Investments Co. acquired a new stake in Viewray Inc (NASDAQ:VRAY) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 17,489 shares of the company’s stock, valued at approximately $121,000.

Several other hedge funds have also recently bought and sold shares of VRAY. BlackRock Inc. increased its holdings in Viewray by 0.4% during the 1st quarter. BlackRock Inc. now owns 1,859,946 shares of the company’s stock worth $11,960,000 after purchasing an additional 6,678 shares during the period. Schwab Charles Investment Management Inc. increased its holdings in Viewray by 15.6% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 61,260 shares of the company’s stock worth $394,000 after purchasing an additional 8,260 shares during the period. Raymond James Financial Services Advisors Inc. purchased a new stake in Viewray during the 2nd quarter worth about $131,000. Barclays PLC increased its holdings in Viewray by 416.1% during the 1st quarter. Barclays PLC now owns 25,041 shares of the company’s stock worth $161,000 after purchasing an additional 20,189 shares during the period. Finally, Russell Investments Group Ltd. increased its holdings in Viewray by 8.4% during the 1st quarter. Russell Investments Group Ltd. now owns 407,151 shares of the company’s stock worth $2,618,000 after purchasing an additional 31,416 shares during the period. Hedge funds and other institutional investors own 91.37% of the company’s stock.

Several brokerages have weighed in on VRAY. Cantor Fitzgerald restated a “buy” rating and set a $13.00 price target on shares of Viewray in a report on Wednesday, October 3rd. BidaskClub downgraded Viewray from a “buy” rating to a “hold” rating in a report on Wednesday, August 8th. BTIG Research restated a “buy” rating and set a $14.00 price target on shares of Viewray in a report on Tuesday, August 7th. Mizuho restated a “buy” rating and set a $13.00 price target on shares of Viewray in a report on Monday, August 6th. Finally, ValuEngine upgraded Viewray from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 24th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $12.58.

Shares of NASDAQ:VRAY traded up $0.28 on Friday, hitting $8.74. 1,176,980 shares of the company’s stock were exchanged, compared to its average volume of 1,064,828. The stock has a market cap of $703.93 million, a P/E ratio of -8.40 and a beta of 1.11. Viewray Inc has a 1-year low of $5.50 and a 1-year high of $13.21. The company has a debt-to-equity ratio of 1.17, a quick ratio of 2.64 and a current ratio of 3.33.

Viewray (NASDAQ:VRAY) last released its quarterly earnings data on Friday, August 3rd. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.09). The business had revenue of $16.44 million for the quarter, compared to analyst estimates of $15.97 million. Viewray had a negative return on equity of 353.05% and a negative net margin of 83.84%. The company’s revenue was up 2255.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.15) earnings per share. On average, equities research analysts predict that Viewray Inc will post -0.76 EPS for the current year.

In related news, insider Fmr Llc sold 258,565 shares of the company’s stock in a transaction dated Monday, July 30th. The stock was sold at an average price of $11.51, for a total value of $2,976,083.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Orbimed Advisors Llc sold 169,920 shares of the company’s stock in a transaction dated Tuesday, August 7th. The shares were sold at an average price of $11.20, for a total value of $1,903,104.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 3,436,496 shares of company stock valued at $36,326,958. Insiders own 43.93% of the company’s stock.

Viewray Profile

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Further Reading: Cash Flow Analysis in Stock Selection

Institutional Ownership by Quarter for Viewray (NASDAQ:VRAY)

Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.